Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Seelos Therapeutics Inc News

    0,291 $ +1,89% +0,0054 $
    In : 0,2721 € | 26.04.24 22:00:00 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3ESGY
    ISIN: US81577F2083
    US-Symbol: SEEL
    Typ: Aktie

    Seelos Therapeutics Inc News

    19.03.24 - PR Newswire
    Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
    Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose) PR Newswire
    26.01.24 - PR Newswire
    Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
    Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-​the-Market Under Nasdaq Rules PR Newswire
    22.01.24 - PR Newswire
    Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002
    Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the ...
    02.01.24 - PR Newswire
    Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024
    Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024 PR Newswire
    22.12.23 - PR Newswire
    Seelos Therapeutics, Inc. Releases Letter to its Stockholders
    Seelos Therapeutics, Inc. Releases Letter to its Stockholders PR Newswire
    01.12.23 - PR Newswire
    Seelos Therapeutics Announces Closing of Public Offering
    Seelos Therapeutics Announces Closing of Public Offering PR Newswire
    01.12.23 - PR Newswire
    Thinking about buying stock in Neximmune, ShiftPixy, Ampio Pharmaceuticals, Seelos Therapeutics, or Nio Inc?
    Thinking about buying stock in Neximmune, ShiftPixy, Ampio Pharmaceuticals, Seelos Therapeutics, or Nio Inc? PR Newswire
    29.11.23 - PR Newswire
    Thinking about buying stock in RedHill Biopharma, Mynaric, Energy Transfer LP, Seelos Therapeutics, or Petco Health and Wellness?
    Thinking about buying stock in RedHill Biopharma, Mynaric, Energy Transfer LP, Seelos Therapeutics, or Petco Health and Wellness? PR Newswire
    28.11.23 - PR Newswire
    Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
    Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering PR Newswire
    28.11.23 - PR Newswire
    Seelos Therapeutics Announces Proposed Public Offering
    Seelos Therapeutics Announces Proposed Public Offering PR Newswire
    27.11.23 - PR Newswire
    Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)
    Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate ...
    24.11.23 - PR Newswire
    Seelos Therapeutics Announces 1-for-30 Reverse Stock Split
    Seelos Therapeutics Announces 1-for-30 Reverse Stock Split PR Newswire
    27.10.23 - PR Newswire
    Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023
    Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023 PR Newswire
    17.10.23 - PR Newswire
    Seelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations
    Seelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations PR Newswire
    28.09.23 - PR Newswire
    Thinking about buying stock in Oncolytics Biotech, Near Intelligence, Basin Uranium, Seelos Therapeutics, or MillerKnoll?
    Thinking about buying stock in Oncolytics Biotech, Near Intelligence, Basin Uranium, Seelos Therapeutics, or MillerKnoll? PR Newswire
    28.09.23 - PR Newswire
    Thinking about buying stock in Seelos Therapeutics, West Red Lake Gold Mines, Immunovant, MSP Recovery, or Transcode Therapeutics?
    Thinking about buying stock in Seelos Therapeutics, West Red Lake Gold Mines, Immunovant, MSP Recovery, or Transcode Therapeutics? PR Newswire
    27.09.23 - PR Newswire
    Thinking about buying stock in American Lithium, Avalo Therapeutics, Seelos Therapeutics, Rivian Automotive, or Immunovant?
    Thinking about buying stock in American Lithium, Avalo Therapeutics, Seelos Therapeutics, Rivian Automotive, or Immunovant? PR Newswire
    27.09.23 - PR Newswire
    Seelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease
    Seelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease PR Newswire
    21.09.23 - PR Newswire
    Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock
    Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock PR Newswire
    20.09.23 - PR Newswire
    Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide
    Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide PR Newswire

    Newssuche

    Videos

    newspaper
    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »